Table 6.
Base case results
| BSC | VN | Incremental | |
|---|---|---|---|
| VN acquisitiona, administration and monitoring costs | £0 | £617,873 | £617,873 |
| Eligibility testing costs | £0 | £142 | £142 |
| Adverse event costs | £0 | £165 | £165 |
| Healthcare resource use costs | £57,050 | £51,274 | − £5776 |
| Total costs | £57,050 | £669,454 | £612,404 |
| Total QALYs | 9.8 | 16.3 | 6.4 |
| ICER | – | – | £95,072 |
BSC best supportive care, CF counting fingers, HM hand motion, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, VI visual impairment, VN voretigene neparvovec
aList price—note that in the UK a confidential discount to the list price is available